18:20 : Threshold Pharmaceuticals ([[THLD]] +4.5%), which rallied today after ... -
Threshold Pharmaceuticals (THLD +4.5%), which rallied today after its TH-302 drug received orphan status from the FDA, falls 2.3% AH after providing detailed clinical results for the drug's Phase 2b trials, which evaluate ...
06:34 : Threshold Pharmaceuticals Receives US Orphan Drug Designation for TH-302 ... -
SOUTH SAN FRANCISCO, CA--(Marketwire - Mar 30, 2012) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced the US Food and Drug Administration (FDA) has granted Orphan Drug Designation for TH-302, a hypoxia-targeted ...
07:01 : Threshold Pharmaceuticals (THLD) receives orphan drug designation in the ... -
Threshold Pharmaceuticals (THLD) receives orphan drug designation in the EU for its TH-302 treatment for soft tissue sarcoma after early studies showed positive results with patients. The company is currently in critical ...
06:39 : Threshold Pharmaceuticals' TH-302 to Be Featured at Symposium on Hypoxia ... -
SOUTH SAN FRANCISCO, CA--(Marketwire - Mar 12, 2012) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) announced that TH-302 will be featured among several presentations by academic and industry experts at a symposium entitled ...
05:38 : Threshold Pharmaceuticals Announces Oral Presentation on TH-302 Clinical ... -
SOUTH SAN FRANCISCO, CA--(Marketwire - Mar 6, 2012) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that a Late-Breaking clinical abstract has been selected for presentation at the American Association ...
05:23 : Threshold Pharmaceuticals Announces Promising Phase 1 Clinical Trial Result -
SOUTH SAN FRANCISCO, CA--(Marketwire - Dec 14, 2011) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced clinical trial results of the Phase 1 study of TH-302 in patients with advanced leukemias conducted ...
05:18 : Threshold Pharmaceuticals Announces Update to TH-302 Pancreatic Data to ... -
SOUTH SAN FRANCISCO, CA--(Marketwire - Dec 13, 2011) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Threshold's Chief Executive Officer, is scheduled to present an update at the ...
11:29 : Threshold Pharmaceuticals to Present at Rodman & Renshaw 13th Annual Health -
REDWOOD CITY, CA--(Marketwire - Sep 6, 2011) - Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Dr. Barry Selick, Threshold's Chief Executive Officer, is scheduled to present at the Rodman and Renshaw|Rodman ...